2.47 USD
▼+0.03-4.63%
盘后 2.64 +1.93%
2026-08-03
市值
$10.95M
市盈率
—
EPS
-2.66
股息率
—
52 周区间
1.77 – 3.01
成交量
40.46K
Beta
-0.34
目标价
—
52W 低 1.7752W 高 3.01
价格走势
公司简介
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...